Galecto Inc (GLTO) Stock Price, Quote & News

Company Profile

Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 70 52 10

Website: galecto.com

Address:

Ole Maaloes Vej 3, Copenhagen N, Copenhagen, Denmark

skyrockets_Inc Oct. 24 at 7:25 PM

$BOLT Update to chart. Still holding 100 and 50 day SMA with solid support. $15/share in cash. 0 debt. Low float 1.92m shares. 40% institutional ownership w/ TANG owning 8%. BDC-4182 in clinical trials and BDC-3042 in partnering search process. Still maintaining ISAC collaborations w/ big pharma partners Genmab and Toray. Easy buyout candidate at these levels. I'm buying more. Next week should be fire. Low float biotechs have been hot lately. Just looks at what $NERV and $GLTO did recently.

0 · Reply

CEMBP_Trader Oct. 23 at 11:15 PM

$GLTO Added 🍀🎉🍀

0 · Reply

ryerson1 Oct. 23 at 10:05 PM

$GLTO something is brewing here , someone knows something here. This will run again to 30.00 + and shorts will Pyle in again .

0 · Reply

CEMBP_Trader Oct. 23 at 8:18 PM

$GLTO Company needs cash badly, but it still hasn’t did a secondary. What is the chance the company is working on a NERV type financing while interest rate is starting to go down. If some type of decent financing or asset sales announcement soon, the short squeeze of the remaining 10/7/25 shorts would be unbelievably massive. 🍀🎉🍀

0 · Reply

DaarT5903 Oct. 23 at 8:17 PM

$GLTO if this could go up really high so I can make my money back and sell that would be great 😂🥲

0 · Reply

STKH Oct. 23 at 1:51 PM

$GLTO

0 · Reply

CEMBP_Trader Oct. 22 at 9:36 PM

$GLTO Starter for another round to swing. 🍀🎉🍀

0 · Reply

rekked87 Oct. 22 at 5:39 AM

$GLTO seeing a 9.40 overnight price

0 · Reply

rekked87 Oct. 21 at 11:03 PM

$GLTO 7 next

0 · Reply

skyrockets_Inc Oct. 21 at 6:33 PM

$BOLT Looking real good. Holding strong above the 100SMA. Volume steadily increasing the past 30 days. Something is coming soon imo. $NERV did it today as I mentioned before. Same w/ $GLTO. 2 for 2. $BOLT is next.

0 · Reply

What's Going On With Nano-Cap Galecto Stock On Tuesday?

Oct 7, 2025, 10:27 AM EDT - 17 days ago

Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble

Aug 5, 2025, 4:15 PM EDT - 2 months ago

Galecto Reports Second Quarter 2025 Operating and Financial Results

May 8, 2025, 4:30 PM EDT - 6 months ago

Galecto Reports First Quarter 2025 Operating and Financial Results

Mar 19, 2025, 4:45 PM EDT - 7 months ago

Galecto Reports Full-Year 2024 Financial Results

Feb 6, 2025, 8:00 AM EST - 9 months ago

Galecto to Participate in Upcoming Investor Conferences

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Galecto Reports Third Quarter 2024 Financial Results

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

Oct 7, 2024, 8:45 AM EDT - 1 year ago

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Aug 28, 2024, 9:00 AM EDT - 1 year ago

Galecto Announces Reverse Stock Split

May 1, 2024, 4:01 PM EDT - 1 year ago

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

Dec 21, 2023, 4:05 PM EST - 2 years ago

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

Sep 26, 2023, 4:01 PM EDT - 2 years ago

Galecto Announces Plans to Explore Strategic Alternatives

Sep 14, 2023, 8:15 AM EDT - 2 years ago

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

GALT

Aug 31, 2023, 11:00 AM EDT - 2 years ago

Galecto to Present at Investor Conferences in September

Aug 15, 2023, 8:39 AM EDT - 2 years ago

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Aug 15, 2023, 7:55 AM EDT - 2 years ago

Galecto to discontinue development of lung disease treatment

Aug 15, 2023, 7:30 AM EDT - 2 years ago

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Jul 31, 2023, 4:05 PM EDT - 2 years ago

Galecto Reports Second Quarter Operating and Financial Results

Jun 20, 2023, 8:58 AM EDT - 2 years ago

Galecto Set to Join Russell Microcap® Index

May 30, 2023, 8:00 AM EDT - 2 years ago

Galecto to Present at the Upcoming Jefferies Healthcare Conference

May 23, 2023, 8:30 AM EDT - 2 years ago

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

May 17, 2023, 4:01 PM EDT - 2 years ago

Galecto to Present Poster at Upcoming ATS 2023 International Conference

Apr 28, 2023, 8:00 AM EDT - 2 years ago

Galecto Reports First Quarter Operating and Financial Results

Apr 18, 2023, 7:01 PM EDT - 2 years ago

Galecto: Promising Pipeline And Excellent Risk-Reward

Apr 13, 2023, 8:30 AM EDT - 2 years ago

Galecto to Present Two Posters at AACR Annual Meeting 2023

Mar 9, 2023, 7:00 AM EST - 2 years ago

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022

Mar 2, 2023, 4:05 PM EST - 2 years ago

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Feb 1, 2023, 8:00 AM EST - 2 years ago

Galecto to Participate in SVB Securities Global Biopharma Conference

Dec 7, 2022, 4:05 PM EST - 3 years ago

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting

Nov 8, 2022, 9:15 AM EST - 3 years ago

Galecto Reports Third Quarter Operating and Financial Results

Nov 8, 2022, 6:00 AM EST - 3 years ago

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

Nov 3, 2022, 8:00 AM EDT - 3 years ago

Galecto to Participate in Jefferies London Healthcare Conference

Oct 31, 2022, 8:00 AM EDT - 3 years ago

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

Oct 19, 2022, 8:00 AM EDT - 3 years ago

Galecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Oct 17, 2022, 6:00 AM EDT - 3 years ago

Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022

Sep 29, 2022, 10:11 AM EDT - 3 years ago

Galecto ($GLTO) Phase 2a Trial Reduces Fibrosis of Bone Marrow in Patients with Myelofibrosis

Sep 29, 2022, 6:00 AM EDT - 3 years ago

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target

Sep 6, 2022, 8:30 AM EDT - 3 years ago

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

Aug 29, 2022, 8:30 AM EDT - 3 years ago

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

May 31, 2022, 8:30 AM EDT - 3 years ago

Galecto to Participate at Jefferies Healthcare Conference

May 26, 2022, 8:30 AM EDT - 3 years ago

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

Apr 26, 2022, 8:30 AM EDT - 3 years ago

Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Mar 29, 2022, 8:30 AM EDT - 3 years ago

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Feb 17, 2022, 5:00 PM EST - 4 years ago

Galecto Reports Financial Results for the Year Ended December 31, 2021

Jan 27, 2022, 7:00 AM EST - 4 years ago

Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care

Dec 13, 2021, 8:00 AM EST - 4 years ago

Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial

Nov 2, 2021, 11:26 AM EDT - 4 years ago

Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting

Nov 2, 2021, 8:00 AM EDT - 4 years ago

Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer

skyrockets_Inc Oct. 24 at 7:25 PM

0 · Reply

CEMBP_Trader Oct. 23 at 11:15 PM

$GLTO Added 🍀🎉🍀

0 · Reply

ryerson1 Oct. 23 at 10:05 PM

$GLTO something is brewing here , someone knows something here. This will run again to 30.00 + and shorts will Pyle in again .

0 · Reply

CEMBP_Trader Oct. 23 at 8:18 PM

0 · Reply

DaarT5903 Oct. 23 at 8:17 PM

$GLTO if this could go up really high so I can make my money back and sell that would be great 😂🥲

0 · Reply

STKH Oct. 23 at 1:51 PM

$GLTO

0 · Reply

CEMBP_Trader Oct. 22 at 9:36 PM

$GLTO Starter for another round to swing. 🍀🎉🍀

0 · Reply

rekked87 Oct. 22 at 5:39 AM

$GLTO seeing a 9.40 overnight price

0 · Reply

rekked87 Oct. 21 at 11:03 PM

$GLTO 7 next

0 · Reply

skyrockets_Inc Oct. 21 at 6:33 PM

0 · Reply

rekked87 Oct. 21 at 6:09 PM

$GLTO baggies unite

0 · Reply

Slitherin Oct. 21 at 9:27 AM

PLRZ is the best biotech squeezer. $15M cash and no debt. Cash to fund operations for the next 50 months with no dilution. Very early hear and expecting news soon. $BYND $OPEN $ATMV $GLTO $XBIO worth watching as well

1 · Reply

Pharoh42 Oct. 20 at 10:28 PM

$GLTO What a waste of money on this pile of 💩

0 · Reply

Twills08 Oct. 20 at 4:26 AM

$GLTO watching...

0 · Reply

brptrader Oct. 17 at 5:55 PM

$GLTO ssr monday.. lol

0 · Reply

rekked87 Oct. 17 at 5:48 PM

0 · Reply

brptrader Oct. 17 at 5:37 PM

$GLTO thia is bad

0 · Reply

_NotFinancialAdvice_ Oct. 16 at 11:04 PM

$GLTO was sooo going to explode because of FAIL TO DELIVER. Did you read? FAIL TO DELIVER mofos! ahahahahahahahahahahahah Yes indeed; that failed to deliver! fcktard

0 · Reply

SDBiotechInvestor Oct. 16 at 6:05 PM

$SNSE prob has best shot to pull a crazy $SPRB or $GLTO type move tomorrow given the float and data.

0 · Reply

rekked87 Oct. 16 at 5:08 PM

$GLTO wow

0 · Reply

thesharkinthedark Oct. 16 at 11:09 AM

$PRAX SHORTS ARE DONE!!! $SPRB $QNRX $GLTO

0 · Reply

loaflote Oct. 15 at 10:12 PM

$GLTO Good Luck Taking Off

1 · Reply

Market Cap	10.98M
Revenue (ttm)	0.00
Net Income (ttm)	-21.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	175,000
Avg Vol	3,167,610
Day's Range	N/A - N/A
Shares Out	1.33M
Stochastic %K	17%
Beta	1.38
Analysts	Hold
Price Target	$6.00